Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Phase 2 Completed 12 enrolled Dana-Farber Cancer Institute Brigham and Women's Hospital · collab Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma. This drug has been used in chronic myeloid leukemia and information from those other research studies suggests that it may help to treat T cell non-Hodgkin's lymphoma.

Timeline

Start: 2008-06
Primary completion: 2013-10
Completion: 2013-10

Publications

Results Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma. 2015 Apr;56(4):993-8. doi: 10.3109/10428194.2014.941835. Epub 2014 Aug 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	400 mg	Oral
Subject	Imatinib	Small molecule	600 mg	Oral
Subject	Imatinib	Small molecule	800 mg	Oral

Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Summary

Timeline

Publications

Drugs

Indications